The scan doesn't treat anything. It buys you stage shift: the same cancer, found small. Caught late, after it causes a cough that won't quit or coughed-up blood, five-year survival is in the single digits. Caught early and still in one lobe, it's above 60% 1. The scan grabs the tumor in that early window, before you can feel it.
The number holds up across three trials, two continents. The big US trial found 20% fewer lung-cancer deaths in the CT group, and 7% fewer deaths from any cause 2. A European trial run on a different design landed at 24% fewer for men and 33% for women, the gap still widening ten years out 3. Most cancer screening lowers deaths from that one cancer but not deaths overall. Lung CT moves both.
You qualify if all three are true 4: age 50 to 80; at least 20 pack-years; and you smoke now or quit within the last 15 years. A pack-year is a pack a day for a year, so 20 is a pack a day for 20 years, or two packs for 10. Eligibility is what makes it covered and makes the trial odds yours.
The ask is one sentence to your doctor. The rest is a 30-minute appointment.
Most years, nothing happens, and that's the win. The scan comes back clean, your doctor gets a one-page report, your year goes on. The rare loud year is the one where it flags a small early tumor. For stage I disease, a single operation to remove the affected lobe carries five-year survival between 70 and 90% 1, and you're back at work in weeks. Fully using the criteria would prevent about 13% of US lung-cancer deaths in eligible people 6.
The fine print — when to skip it, and what people get wrong
The catch is false alarms. Over three yearly scans, about 40% had one flagged, and 96% of those were not cancer 2. Expect a follow-up scan; the Lung-RADS scoring system roughly halved that rate 7.
Feeling fine is the point of screening, not a reason to skip it — once symptoms arrive the curable window has usually closed. A chest x-ray can't see the small nodules CT catches. And a flagged scan is not a diagnosis: nine in ten flagged spots are benign.
Skip it if you couldn't be treated. If severe heart or lung disease, or a life expectancy under five to ten years, would rule out lung surgery, a finding only generates worry and procedures. Medicare stops covering at 78, USPSTF stops recommending at 81.
- 1NCI SEER Program (2024). Cancer Stat Facts: Lung and Bronchus Cancer. link
- 2Aberle et al. (2011). Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. New England Journal of Medicine. link
- 3de Koning et al. (2020). Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. New England Journal of Medicine. link
- 4USPSTF (2021). Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. link
- 5Tanner et al. (2015). The Association between Smoking Abstinence and Mortality in the National Lung Screening Trial. American Journal of Respiratory and Critical Care Medicine. link
- 6Jonas et al. (2021). Screening for Lung Cancer With Low-Dose Computed Tomography: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. link
- 7Pinsky et al. (2013). Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment. Annals of Internal Medicine. link
დაკავშირებული სახელმძღვანელოში (4)
- — Both this scan and the yearly lung CT are aimed at ex-smokers. If you qualify for one, check whether you're due the other.
- — For long-term smokers, add the annual lung scan to the standard cancer-screening line-up.
- — If you've got COPD from years of smoking, you likely also qualify for annual lung-cancer screening.
- — For a smoker, the proven lung CT is the higher-value move; the multi-cancer test is an unproven add-on, not a replacement.
Lung Cancer Screening
Covered without patient cost-sharing by Medicare and ACA-marketplace plans as a USPSTF grade B preventive service (CMS 2022); cash price for self-pay is roughly $100-400 per annual scan at US imaging centers.
Single supine breath-hold scan, no IV contrast, no preparation; door-to-door time 15-30 minutes once per year, plus a one-time shared-decision-making visit before the first scan.
Two large RCTs (NLST n=53,454 and NELSON n=15,792) plus the Italian MILD trial converge on a 20-33% lung-cancer mortality reduction; USPSTF assigns a grade B recommendation (USPSTF 2021, Jonas et al. 2021 evidence review).
NLST showed a 20% reduction in lung-cancer mortality and 6.7% reduction in all-cause mortality with three annual LDCT scans (Aberle et al. 2011); NELSON replicated at 10 years with 24% and 33% reductions in men and women (de Koning et al. 2020). Among eligible smokers this is one of the larger absolute mortality interventions in the catalogue, with a number-needed-to-screen near 320 over 6.5 years.